Asclepix Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Baltimoremarylandfocused On Developing Innovative Therapies For Ocular Diseases And Cancerfounded In 2011The Company Utilizes Advanced Computational Biology Methods To Create Peptide Based Treatments That Aim To Regulate Vascular Homeostasis And Enhance Patient Health The Company Is Dedicated To Addressing Significant Medical Needs In Its Therapeutic Areasits Clinical Candidates Target Retinal Diseases And Aim To Activate Anti Tumor Immunity In Oncologyimproving The Effectiveness Of Immunotherapyasclepix Therapeutics Has Raised $68 92 Million In Fundingwith Ongoing Efforts To Advance Its Clinical Studiesthe Company Has Also Filed Five Patents Related To Its Researchdemonstrating Its Commitment To Protecting Its Intellectual Property In The Field Of Ocular Diseases
